{"id":14967,"date":"2011-05-01T09:45:20","date_gmt":"2011-05-01T09:45:20","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=14967"},"modified":"2011-05-01T09:45:20","modified_gmt":"2011-05-01T09:45:20","slug":"atazanavirritonavir-and-combined-oral-contraceptives","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/14967","title":{"rendered":"Atazanavir\/ritonavir and combined oral contraceptives"},"content":{"rendered":"<p><strong>HIV-druginteractions.org<\/strong><\/p>\n<p>This was an open-label, three-period, single-sequence student assessing the effect of atazanavir\/ritonavir on the pharmacokinetics of oral contraceptive containing either 35 microgram ethinyl estradiol plus norgestimate (OC given alone for days 1-28) or 25 microgram ethinyl estradiol plus norgestimate (OC given with atazanavir\/r on days 29-42).<\/p>\n<p>Reductions of approximately 20% in ethinyl estradiol levels were seen, whereas the concentrations of 17-deacetyl norgestimate (active metabolite) were increased (AUC by 85%, Cmin by 102%).<\/p>\n<p>The authors concluded that increasing the ethinyl estradiol component to 30-35 microgram when co-administered with atazanavir\/ritonavir might be desirable to minimise breakthrough bleeding.<\/p>\n<p>Reference:<\/p>\n<p>Zhang J et al. The effect of atazanavir\/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women. Antivir Ther, 2011, 16(2): 157-164.<br \/>\n<a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21447864\">http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21447864<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>HIV-druginteractions.org This was an open-label, three-period, single-sequence student assessing the effect of atazanavir\/ritonavir on the pharmacokinetics of oral contraceptive containing either 35 microgram ethinyl estradiol plus norgestimate (OC given alone for days 1-28) or 25 microgram ethinyl estradiol plus norgestimate &hellip;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[],"class_list":["post-14967","post","type-post","status-publish","format-standard","hentry","category-pk-and-drug-interactions"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/14967","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=14967"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/14967\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=14967"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=14967"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=14967"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}